Neurology News

For individuals with pediatric-onset multiple sclerosis, treatment with commonly known highly effective therapies was associated with reduced relapse risk and optimal outcome within the first 2 years, researchers wrote in JAMA Neurology.

The FDA has granted fast track designation to an investigational peptide-conjugated antisense oligonucleotide delivery system to treat myotonic dystrophy type 1, according to the manufacturer.

In this episode, host Shikha Jain, MD, speaks with Ashley Sumrall, MD, about advocacy outside of their oncology practices and organizations, what lies ahead for the field of neuro-oncology and more.

The first subject has been dosed in a phase 1 clinical trial of an oral proteolysis-targeting chimera protein degrader to treat neurodegenerative diseases, according to the manufacturer.

The FDA has granted rare pediatric disease designation to an investigational therapy for the treatment of Duchenne muscular dystrophy in those with mutations amenable to exon 44 skipping, according to the manufacturer.

Acetylcholinesterase inhibitors used to treat Alzheimer’s disease may also reduce the risk for developing age-related macular degeneration, according to a cohort study of older veterans published in JAMA Ophthalmology.

In a cohort of post-9/11 United States military veterans, moderate, severe and penetrating traumatic brain injuries were associated with the subsequent development of brain cancer, according to research from JAMA Network Open.

The new CMS rule aiming to streamline prior authorization signals a major step forward for primary care, but the process could still use some improvement, according to experts.

Researchers reported that a population-based study shows statin use among older adults with heart failure was associated with a 20% lower risk for all-cause dementia, including a 28% reduction in risk for developing Alzheimer’s disease.

Otsuka has announced that a phase 3 clinical trial of AVP-786, a combination therapy to treat agitation associated with dementia due to Alzheimer’s disease, failed to achieve its primary endpoints.